Navigation Links
Halozyme Confirms Baxter Has Received A Complete Response Letter For HyQ BLA

SAN DIEGO, Aug. 1, 2012 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that the Center for Biologics Evaluation and Research (CBER) of the U.S. Food and Drug Administration (FDA) has issued a complete response letter (CRL) for Baxter's HyQ Biologics License Application (BLA). HyQ is an investigational product that includes plasma-derived Immune Globulin (IG) 10% and Halozyme's recombinant human hyaluronidase (rHuPH20) for subcutaneous administration in patients with primary immunodeficiency disease.

(Logo: )

The letter requested additional preclinical data to support the BLA. The primary issues raised in the letter focused on non-neutralizing antibodies generated against recombinant human hyaluronidase and the possible effects of these antibodies on reproduction, development and fertility. Elevated anti-rHuPH20 antibody titers were detected in the registration trial, but have not been associated with any adverse events.

Pending the parties providing additional preclinical data sufficient to address the regulatory questions, CBER has requested that patients should no longer be dosed with rHuPH20 in the Baxter and ViroPharma clinical studies.

Halozyme has been in contact with the Center for Drug Evaluation and Research (CDER) regarding the impact on Hylenex® recombinant (hyaluronidase human injection). CDER is the division of FDA regulating the other investigational rHuPH20 programs, including insulin and PEGPH20. After reviewing the data, CDER has confirmed that there is no need for actions against Hylenex or clinical programs in the Hylenex IND.

"With receipt of the CRL, we can directly address the questions raised by CBER," said Gregory I. Frost, Ph.D., President and Chief Executive Officer, Halozyme. "We look forward to collaborating with the agency to address their concerns."

Conference Call, August 1, 2012

The Company will host a conference call today, August 1, 2012, at 1:30 pm PT/4:30 pm ET to discuss this development. Gregory I. Frost, President and Chief Executive Officer, will lead the call.

The call will be webcast live through the "Investors" section of Halozyme's corporate website and a recording will be made available following the close of the call. To access the webcast, please log on to approximately fifteen minutes prior to the call to register, download and install any necessary audio software. For those without access to the Internet, the live call may be accessed by phone by calling (877) 407-8037 (domestic callers) or (201) 689-8037 (international callers). A telephone replay will be available shortly after the call by dialing (877) 660-6853 (domestic callers) or (201) 612-7415 (international callers) using account number 367 and replay ID number 398405.

About Halozyme

Halozyme Therapeutics is a biopharmaceutical company dedicated to developing and commercializing innovative products that advance patient care. With a diversified portfolio of enzymes that target the extracellular matrix, the Company's research focuses primarily on a family of human enzymes, known as hyaluronidases, that increase the absorption and dispersion of biologics. Halozyme's pipeline addresses therapeutic areas, such as diabetes, oncology and dermatology that have significant unmet medical need. The Company markets Hylenex® recombinant (hyaluronidase human injection) and has partnerships with Roche, Baxter, ViroPharma and Intrexon. Halozyme is headquartered in San Diego, CA. For more information on how we are innovating, please visit our corporate website at

Safe Harbor Statement
In addition to historical information, the statements set forth above include forward-looking statements (including, without limitation, statements concerning our products in development, potential benefits and attributes, anticipated clinical and regulatory events and our intended actions) that involve risk and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. The forward-looking statements are also identified through use of the words "believe," "enable," "may," "will," "could," "intends," "estimate," "anticipate," "plan," "predict," "probable," "potential," "possible," "should," "continue," and other words of similar meaning. Actual results could differ materially from the expectations contained in forward-looking statements as a result of several factors, including clinical trial enrollment and results, regulatory requirements, adverse effects associated with the use of our products, and competitive conditions. These and other factors that may result in differences are discussed in greater detail in the Company's Quarterly Report on Form 10-Q, filed with the Securities and Exchange Commission on May 7, 2012.

Media/Investor Contacts:

Halozyme (US)
Anne Erickson
Executive Director
Halozyme Therapeutics

Halozyme (EU) - Media
Danielle Whitney
+44 (0)7827 860 310

SOURCE Halozyme
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Halozymes Ultrafast Insulin Formulations Improved Postprandial Glycemic Control in Patients Living with Type 1 Diabetes: Phase 2 Study Results Presented at ADA 2012
2. Halozyme Therapeutics to Present at the Jefferies 2012 Global Healthcare Conference
3. Halozyme Reports First Quarter 2012 Financial Results
4. Halozyme to Host First Quarter 2012 Financial Results Conference Call
5. Lilly Confirms Date and Conference Call for Second-Quarter 2012 Financial Results Announcement
6. Study Confirms Daniels Sharpsmart Helps Hospitals Reduce Carbon Footprint
7. Watson Confirms Testim® Patent Challenge
8. Watson Confirms Lo Loestrin® Fe Patent Challenge
9. Sirnaomics Received NIH SBIR Grant for Developing Its Scarless Wound Healing siRNA Therapeutics
10. Hologic Completes Acquisition Of Gen-Probe
11. United Seating & Mobility Completes Acquisition of Active American Mobilitys Rehab Division
Post Your Comments:
(Date:10/13/2015)... Oct. 13, 2015  EndoChoice Holdings, Inc. (NYSE:  GI) ... 2015 financial results on Thursday, November 5, 2015 before ... --> . --> ... 5, 2015 at 9:00 a.m. ET to discuss the ... callers and (412) 317-5469 for international callers. A live ...
(Date:10/13/2015)... SAN DIEGO , October 13, 2015 ... RGBP) today announced the appointment of Harry Lander , ... with the Company,s Chairman & CEO David Koos ... in small molecule and immuno-oncological therapeutics. --> ... announced the appointment of Harry Lander , PhD as ...
(Date:10/13/2015)... , Oct. 13, 2015 China Jo-Jo ... " China Jo-Jo "), a leading China-based retail, wholesale ... through its own online and retail pharmacies, announced preliminary ... official branded online pharmacy through , growing ... a record 25%. China Jo-Jo,s ...
Breaking Medicine Technology:
(Date:10/13/2015)... ... , ... Sir Grout of Greater Boston donated an expansive, seven room ... House Charities® (RMHC®). This donation was made in an effort to give back to ... inception. , “We believe strongly in the Ronald McDonald House Charities, and they are ...
(Date:10/13/2015)... PA (PRWEB) , ... October 13, 2015 , ... "My ... digging his fists into his infected cheeks," said an inventor from Platteville, Colo. "I ... their skin problems." , He developed the UNTOUCHABLE to prevent a child from rubbing ...
(Date:10/13/2015)... , ... October 13, 2015 , ... ... anesthesia and pain management services, today announced its partnership with WPC Healthcare ... data from disparate systems and organizes the data into an aggregated data repository ...
(Date:10/13/2015)... ... October 13, 2015 , ... According to an article ... has shown that women who successfully lose weight with a bariatric procedure are much ... each year. The article notes that anywhere from 40 to 50 percent of all ...
(Date:10/13/2015)... Hills, CA (PRWEB) , ... October 13, 2015 ... ... management and workflow solutions, announced today their sponsorship of the Microsoft Dynamics AXUG, ... Reno-Tahoe, Nevada. AXUG Summit, GPUG Summit and NAVUG Summit are independent user conferences ...
Breaking Medicine News(10 mins):